JPH09169655A - Topical powder for skin ulcer - Google Patents
Topical powder for skin ulcerInfo
- Publication number
- JPH09169655A JPH09169655A JP33314595A JP33314595A JPH09169655A JP H09169655 A JPH09169655 A JP H09169655A JP 33314595 A JP33314595 A JP 33314595A JP 33314595 A JP33314595 A JP 33314595A JP H09169655 A JPH09169655 A JP H09169655A
- Authority
- JP
- Japan
- Prior art keywords
- weight
- powder
- iodine
- water
- skin ulcer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010040943 Skin Ulcer Diseases 0.000 title claims abstract description 18
- 231100000019 skin ulcer Toxicity 0.000 title claims abstract description 18
- 229940098956 topical powder Drugs 0.000 title 1
- 239000000843 powder Substances 0.000 claims abstract description 51
- 229920002678 cellulose Polymers 0.000 claims abstract description 19
- 239000001913 cellulose Substances 0.000 claims abstract description 19
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000011630 iodine Substances 0.000 claims abstract description 18
- 229910052740 iodine Inorganic materials 0.000 claims abstract description 18
- 235000000346 sugar Nutrition 0.000 claims abstract description 18
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229920000153 Povidone-iodine Polymers 0.000 claims abstract description 13
- 229960001621 povidone-iodine Drugs 0.000 claims abstract description 13
- 239000011230 binding agent Substances 0.000 claims abstract description 9
- 229940125810 compound 20 Drugs 0.000 claims abstract 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims description 21
- 229930006000 Sucrose Natural products 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 11
- 239000005720 sucrose Substances 0.000 claims description 11
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 7
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 abstract description 18
- 210000000416 exudates and transudate Anatomy 0.000 abstract description 7
- 230000007794 irritation Effects 0.000 abstract description 3
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 238000010979 pH adjustment Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 206010052428 Wound Diseases 0.000 description 16
- 238000010521 absorption reaction Methods 0.000 description 12
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 5
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 5
- 229950008138 carmellose Drugs 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 229960001681 croscarmellose sodium Drugs 0.000 description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
- 238000004898 kneading Methods 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- -1 carboxymethyl ethyl Chemical group 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- TURGQPDWYFJEDY-UHFFFAOYSA-N 1-hydroperoxypropane Chemical class CCCOO TURGQPDWYFJEDY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
(57)【要約】
【課題】 流動性に優れ、創面に自由に散布することが
でき、取り扱いも容易であるという従来のポビドンヨー
ド散剤の利点を保持しつつ、更にpH調整を行うことな
く刺激性を少なくし、又創面の滲出液を吸収し、かつ除
去し易い形態を有する皮膚潰瘍用外用散剤を提供せんと
するものである。
【解決手段】 糖60〜80重量%、水膨潤性セルロー
ス化合物20〜40重量%、結合剤0.5〜3.0重量%
およびヨードホール0.5〜10重量%からなる皮膚潰
瘍用外用散剤。(57) 【Abstract】 PROBLEM TO BE SOLVED: While maintaining the advantages of conventional povidone-iodine powders, which have excellent fluidity, can be freely sprayed on the wound surface, and are easy to handle, irritation without further pH adjustment. It is intended to provide an external powder for skin ulcers which has a form that reduces the amount of bleeding, absorbs exudate on the wound surface and is easy to remove. SOLUTION: Sugar 60 to 80% by weight, water-swellable cellulose compound 20 to 40% by weight, binder 0.5 to 3.0% by weight.
And an external powder for skin ulcer, which comprises 0.5 to 10% by weight of iodine.
Description
【0001】[0001]
【発明の属する技術分野】本発明は、皮膚潰瘍用外用散
剤に関し、さらに詳しくは糖およびヨードホールを有効
成分とする皮膚潰瘍用外用散剤に関する。TECHNICAL FIELD The present invention relates to an external powder for skin ulcer, and more particularly to an external powder for skin ulcer containing sugar and iodine as active ingredients.
【0002】[0002]
【従来の技術】ヨードホールは強力な殺菌力を有し、し
かも刺激性や組織障害が低いことから、手指の消毒や手
術部位の消毒などに使用されており、また蜂蜜、糖蜜、
蔗糖などの糖は火傷や創傷の治療に古くから使用されて
いる。2. Description of the Related Art Iodophor has a strong bactericidal activity, and since it has low irritation and tissue damage, it is used for disinfecting fingers and surgical sites, and honey, molasses,
Sugar such as sucrose has long been used to treat burns and wounds.
【0003】ヨードの殺菌作用、糖の肉芽形成促進作用
を期待して、ヨードホールと糖を主成分とする軟膏が大
学病院内で調剤され使用されている。このような製剤の
改良されたものとして、糖、ポビドンヨード、水および
pHを調整する緩衝剤からなる軟膏剤が知られている
(特公平1−32210)。この製剤においては、ポビ
ドンヨードの含量が一定でない、ポビドンヨードと糖と
の練合が困難である、製剤が二層に分離する、有効成分
が分解して薬効が低下する等の従来の軟膏剤の欠点が克
服されており、広く市販されている。しかしながら、こ
の軟膏剤は、固く延びが悪く、創面に塗布しにくいこと
が指摘されており、また創面からの滲出液の吸収が十分
でないという難点を有している。With the expectation of the bactericidal action of iodine and the granulation formation promoting action of sugar, an ointment mainly containing iodine and sugar is prepared and used in university hospitals. As an improved product of such a preparation, an ointment comprising sugar, povidone iodine, water and a buffer for adjusting pH is known (Japanese Patent Publication No. 1-23210). In this formulation, the content of povidone iodine is not constant, the mixing of povidone iodine and sugar is difficult, the formulation is separated into two layers, the active ingredient is decomposed and the medicinal effect is lowered, and the drawbacks of conventional ointments. Has been overcome and is widely marketed. However, it has been pointed out that this ointment is hard and has poor spreadability and is difficult to apply to the wound surface, and has a drawback that absorption of exudate from the wound surface is not sufficient.
【0004】創面への適用を容易にすべく、ヨードホー
ルを溶かした溶液を微細な糖にスプレーしたヨードホー
ル含有の自由流動性の創傷用散剤(特開昭61−215
324)が提案されている。また、溶液形態のヨードホ
ール製剤が取り扱いに難点のあることから、水溶性ヨー
ドホールと尿素または糖アルコール(特にマンニトー
ル)からなる顆粒または粉末形態のヨードホール組成物
(特開昭63−77805)が提案されている。これら
のヨードホール製剤は均質性と流動性に優れ、創面に自
由に散布することができ、取り扱いも容易であるという
利点を有している。しかしながら、いずれの製剤も水溶
性であるため、創面に適用した際に滲出液の吸収が、必
ずしも十分でない。To facilitate application to the wound surface, a free-flowing wound powder containing iodine, which is obtained by spraying a fine sugar with a solution in which iodine is dissolved (JP-A-61-215).
324) has been proposed. In addition, since the iodine preparation in the form of a solution is difficult to handle, an iodine composition in the form of a granule or a powder comprising water-soluble iodine and urea or sugar alcohol (particularly mannitol) (Japanese Patent Laid-Open No. 63-77805) has been proposed. Proposed. These iodine-hole preparations have the advantages that they are excellent in homogeneity and fluidity, can be freely sprayed on the wound surface, and are easy to handle. However, since all the formulations are water-soluble, the absorption of exudate when applied to the wound surface is not always sufficient.
【0005】[0005]
【発明が解決しようとする課題】本発明は、流動性に優
れ、創面に自由に散布することができ、取り扱いも容易
であるという従来の散剤の利点を保持しつつ、更にpH
調整を行うことなく刺激性を少なくし、又創面の滲出液
を吸収し、かつ除去し易い形態を有する皮膚潰瘍用外用
散剤を提供せんとするものである。DISCLOSURE OF THE INVENTION The present invention retains the advantages of conventional powders that are excellent in fluidity, can be freely sprayed on the wound surface, and are easy to handle, and further have a pH value.
It is intended to provide an external powder for skin ulcer that has a form that reduces irritation without adjustment, absorbs exudate on the wound surface, and is easy to remove.
【0006】[0006]
【課題を解決するための手段】本発明は、糖60〜80
重量%、水膨潤性セルロース化合物20〜40重量%、
結合剤0.5〜3.0重量%およびヨードホール0.5〜
10重量%からなる皮膚潰瘍用外用散剤よりなる。The present invention provides sugars 60-80.
% By weight, 20 to 40% by weight of water-swellable cellulose compound,
Binder 0.5-3.0% by weight and iodine hole 0.5-
It consists of an external powder for skin ulcer consisting of 10% by weight.
【0007】さらに本発明は、糖と水膨潤性セルロース
化合物とを混合し、該混合物に低級アルカノールに結合
剤を溶解した溶液を加えて練合し、練合物を乾燥後、整
粒した物にヨードホールを加えて混合することからなる
上記皮膚潰瘍用外用散剤の製造方法からなる。Further, according to the present invention, a sugar and a water-swellable cellulose compound are mixed, a solution in which a binder is dissolved in a lower alkanol is added to the mixture, and the mixture is kneaded. The kneaded product is dried and then sized. A method for producing the external powder for skin ulcer, which comprises adding iodine hole to the mixture and mixing.
【0008】本発明における糖としては、肉芽形成促進
作用および静菌作用を有する糖が使用され、その例とし
ては、蔗糖、グルコース、デキストロース、果糖、乳糖
などがあげられる。蔗糖、特に日本薬局方の白糖、精製
白糖が好ましい。配合量は肉芽形成促進作用および静菌
作用を発揮できる量であり、全組成物の60〜80重量
%である。As the sugar in the present invention, a sugar having a granulation promoting action and a bacteriostatic action is used, and examples thereof include sucrose, glucose, dextrose, fructose, lactose and the like. Sucrose, particularly sucrose and purified sucrose of the Japanese Pharmacopoeia, are preferred. The compounding amount is an amount capable of exerting a granulation formation promoting action and a bacteriostatic action, and is 60 to 80% by weight of the total composition.
【0009】本発明で使用される水膨潤性セルロース化
合物とは、水に不溶性であって、水を加えたときに水を
吸収して膨潤するセルロース化合物をいい、その例とし
て、低置換度ヒドロキシプロピルセルロース、カルボキ
シメチルエチルセルロース、カルメロース、カルメロー
スカルシウム、クロスカルメロースナトリウム、結晶セ
ルロース、酢酸セルロースなどがあげられる。これらの
セルロース化合物は吸水性に優れているので、本発明の
散剤を創面に適用したときに滲出液を吸収することがで
きる。特に好適なセルロース化合物は低置換度ヒドロキ
シプロピルセルロースである。このものはセルロースの
低置換度ヒドロキシプロピルエーテルであって、乾燥し
たものを定量するとき、ヒドロキシプロポキシル基5.
0〜16.0%を含む。低置換度ヒドロキシプロピルセ
ルロースなどの水膨潤性セルロース化合物は、通常固形
製剤の結合剤、崩壊剤として全組成物の2.0〜5.0重
量%用いられるが、本発明においては散剤としての流動
性、創面からの吸水能および膨潤による剥離性を高める
ため、全組成物の20〜40重量%用いられる。The water-swellable cellulose compound used in the present invention is a cellulose compound which is insoluble in water and absorbs water to swell when added with water, for example, a low-substituted hydroxy compound. Examples include propyl cellulose, carboxymethyl ethyl cellulose, carmellose, carmellose calcium, croscarmellose sodium, crystalline cellulose, and cellulose acetate. Since these cellulose compounds are excellent in water absorption, they can absorb exudate when the powder of the present invention is applied to the wound surface. A particularly preferred cellulose compound is low substituted hydroxypropyl cellulose. This is a low-substituted hydroxypropyl ether of cellulose, which has a hydroxypropoxy group of 5.
Including 0 to 16.0%. A water-swellable cellulose compound such as low-substituted hydroxypropyl cellulose is usually used as a binder and a disintegrant in a solid preparation in an amount of 2.0 to 5.0% by weight of the total composition, but in the present invention, it is used as a powder. 20 to 40% by weight of the total composition is used in order to improve the properties, the water absorbing ability from the wound surface and the peelability due to swelling.
【0010】結合剤としては、低級アルカノールに易溶
性のヒドロキシプロピルセルロースなど通常外用散剤に
使用されているものが用いられる。使用量は全組成物の
0.5〜3.0重量%である。As the binder, those commonly used in external powders such as hydroxypropyl cellulose which is easily soluble in lower alkanols are used. The amount used is 0.5-3.0% by weight of the total composition.
【0011】本発明で用いられるヨードホールは、ヨウ
素と有機ポリマー例えばポリデキストロースまたはポリ
ビニルピロリドン(ポビドン)の生理学的に許容され得
る複合体である。特にヨウ素とポビドンとの複合体であ
るポビドンヨードが好適に使用される。使用量は全組成
物の0.5〜10重量%、好ましくは1.0〜5.0重量
%である。The iodophor used in the present invention is a physiologically acceptable complex of iodine and an organic polymer such as polydextrose or polyvinylpyrrolidone (povidone). Particularly, povidone iodine, which is a complex of iodine and povidone, is preferably used. The amount used is 0.5 to 10% by weight of the total composition, preferably 1.0 to 5.0% by weight.
【0012】本発明の外用散剤は、糖と水膨潤性のセル
ロース化合物とを混合し、該混合物に適量の低級アルカ
ノールに結合剤を溶解した溶液を加えて練合し、練合物
を乾燥後、整粒した物にヨードホールを加えて混合する
ことによって好適に製造される。上記の混合、練合およ
び造粒の各工程は外用散剤を製造する場合の常法にした
がって実施され得る。低級アルカノールとしては、メタ
ノール、エタノール、イソプロパノールなどが用いられ
るが、エタノールが最も好ましい。上記の各成分は日本
薬局方あるいは日本薬局方外医薬品成分規格に記載のも
のを使用するのが望ましい。The powder for external use of the present invention is prepared by mixing sugar and a water-swelling cellulose compound, kneading the mixture with a solution of a binder dissolved in an appropriate amount of a lower alkanol, and kneading the mixture. It is preferably produced by adding iodine holes to the sized product and mixing them. The above-mentioned steps of mixing, kneading and granulation can be carried out according to a conventional method for producing a powder for external use. As the lower alkanol, methanol, ethanol, isopropanol and the like are used, and ethanol is most preferable. It is desirable to use those listed in the Japanese Pharmacopoeia or the Japanese Pharmacopoeia Standards for Pharmaceutical Ingredients.
【0013】[0013]
【実施例】次に実施例および試験例を示して本発明をさ
らに具体的に説明する。 実施例1 ポビドンヨード 3.0重量% 精製白糖 70.0重量% 低置換度ヒドロキシプロピルセルロース 26.0重量% ヒドロキシプロピルセルロース 1.0重量% 撹拌混合機によりとを混合、回転流動しながら日本
薬局方エタノール適量にを溶かした溶液を加えて練合
・造粒する。これを乾燥し、40メッシュで整粒する。
整粒したものにを加えて混合し外用散剤とする。実施
例1で得た外用散剤は流動性を示し、水分を吸収すると
弾力のある塊となり、皮膚面を刺激することなく剥離容
易となり、水で容易に洗い流すことができる。上記散剤
を40℃で4カ月間密封アルミ袋に保存した場合の外観
を観察した。また糖の含量を高速液体クロマトグラフ法
で、有効ヨウ素の含量を滴定法によりそれぞれ測定し、
残存率を算出した。その結果を表1に示す。表1の結果
から明らかなように、本願発明の散剤は経時的に安定で
ある。EXAMPLES Next, the present invention will be described more specifically by showing Examples and Test Examples. Example 1 Povidone-iodine 3.0% by weight Purified sucrose 70.0% by weight Low-substituted hydroxypropylcellulose 26.0% by weight Hydroxypropylcellulose 1.0% by weight Mixing with a stirrer while rotating and flowing, Japanese Pharmacopoeia Knead and granulate by adding a solution prepared by dissolving an appropriate amount of ethanol. This is dried and sized with 40 mesh.
Add to the sized powder and mix to make a powder for external use. The external use powder obtained in Example 1 exhibits fluidity, and when it absorbs water, it becomes a lump with elasticity, is easily peeled off without irritating the skin surface, and can be easily washed off with water. The appearance of the above powder when stored in a sealed aluminum bag at 40 ° C. for 4 months was observed. The content of sugar is measured by high performance liquid chromatography, and the content of available iodine is measured by titration method.
The residual rate was calculated. Table 1 shows the results. As is clear from the results in Table 1, the powder of the present invention is stable over time.
【0014】[0014]
【表1】 2 カ 月 4 カ 月 実施例1散剤 糖残存率(%) 99.1 99.4 有効ヨウ素残存率(%) 94.5 92.3 外 観 変化なし 変化なし[Table 1] 2 months 4 months Example 1 Powder Remaining rate of sugar (%) 99.1 99.4 Remaining rate of available iodine (%) 94.5 92.3 No change in external appearance No change
【0015】比較例1 ポビドンヨード 3.0重量% 精製白糖 70.0重量% D−マンニトール 26.0重量% ヒドロキシプロピルセルロース 1.0重量% 実施例1の低置換度ヒドロキシプロピルセルロースの
代わりに、公知処方例(特開昭63−77805号)の
糖アルコールであるマンニトールを使用し、実施例1の
製法で外用散剤を調製した。実施例1〜4の散剤と比較
例1の散剤及び本発明で使用する水膨潤性セルロースに
ついて下記の吸水試験を行った。 〔吸水試験法〕Water Absorption Apparatus〔伊東明彦
ら:「病院薬学」Vol.20,No.1,p.43(1994)〕を用い、
試料2gの吸液により電子天秤上のビーカーの液量が減
少し、電子天秤の示す重量が変化するのを経時的に測定
し、その値を読み取り飽和時の量を吸水量とした。その
結果を表2に示す。表2から実施例1〜4の散剤が比較
例1の散剤に比較して優れた吸収能を有することが明ら
かである。特に実施例1の散剤は比較例1の散剤に比べ
7倍(実施例4の散剤は約10倍)の吸水能を有する。
また本発明で使用する水膨潤性セルロースが優れた吸水
能を有することが明らかである。Comparative Example 1 Povidone iodine 3.0% by weight Purified sucrose 70.0% by weight D-mannitol 26.0% by weight Hydroxypropylcellulose 1.0% by weight Instead of the low-substituted hydroxypropylcellulose of Example 1, a known compound was used. A powder for external use was prepared by the production method of Example 1 using mannitol, which is a sugar alcohol of the formulation example (JP-A-63-77805). The following water absorption test was conducted on the powders of Examples 1 to 4, the powder of Comparative Example 1 and the water-swellable cellulose used in the present invention. [Water absorption test method] Water Absorption Apparatus [Akihiko Ito et al .: "Hospital Pharmacy" Vol. 20, No. 1, p. 43 (1994)]
It was measured with time that the liquid amount of the beaker on the electronic balance decreased due to the liquid absorption of 2 g of the sample and the weight indicated by the electronic balance changed, and the value was read and the amount at saturation was taken as the water absorption amount. Table 2 shows the results. It is clear from Table 2 that the powders of Examples 1 to 4 have superior absorption ability as compared with the powder of Comparative Example 1. In particular, the powder of Example 1 has a water absorption capacity 7 times that of the powder of Comparative Example 1 (about 10 times that of the powder of Example 4).
Further, it is clear that the water-swellable cellulose used in the present invention has an excellent water absorbing ability.
【0016】[0016]
【表2】 品 名 吸水量(g数) 実施例1散剤 2.68 実施例2散剤 1.68 実施例3散剤 1.29 実施例4散剤 3.59 比較例1散剤 0.36 D−マンニトール 0.81 低置換度ヒドロキシプロピルセルロース 11.97 カルメロース 4.60 カルメロースカルシウム 9.82 クロスカルメロースナトリウム 13.06 結晶セルロース 5.27 酢酸セルロース 5.65 (温度25.5℃,湿度49%)Table 2 Product name Water absorption (g) Example 1 powder 2.68 Example 2 powder 1.68 Example 3 powder 1.29 Example 4 powder 3.59 Comparative example 1 powder 0.36 D-mannitol 0.81 Low-substituted hydroxypropyl cellulose 11.97 Carmellose 4.60 Carmellose calcium 9.82 Croscarmellose sodium 13.06 Crystalline cellulose 5.27 Cellulose acetate 5.65 (Temperature 25.5 ° C, Humidity 49%)
【0017】実施例2 ポビドンヨード 3.0重量% 精製白糖 65.0重量% カルメロース 35.0重量% ヒドロキシプロピルセルロース 2.0重量% 以上の組成からなる外用散剤を実施例1と同様に製造し
た。Example 2 Povidone-iodine 3.0% by weight Purified sucrose 65.0% by weight Carmellose 35.0% by weight Hydroxypropylcellulose 2.0% by weight An external use powder having the above composition was prepared in the same manner as in Example 1.
【0018】実施例3 ポビドンヨード 3.0重量% 精製白糖 60.0重量% 結晶セルロース 30.0重量% ヒドロキシプロピルセルロース 2.0重量% 以上の組成からなる外用散剤を実施例1と同様に製造し
た。Example 3 Povidone-iodine 3.0% by weight Purified sucrose 60.0% by weight Crystalline cellulose 30.0% by weight Hydroxypropylcellulose 2.0% by weight An external powder having the above composition was prepared in the same manner as in Example 1. .
【0019】実施例4 ポビドンヨード 3.0重量% 精製白糖 70.0重量% クロスカルメロースナトリウム 26.0重量% ヒドロキシプロピルセルロース 1.0重量% 以上の組成からなる外用散剤を実施例1と同様に製造し
た。Example 4 Povidone-iodine 3.0% by weight Purified sucrose 70.0% by weight Croscarmellose sodium 26.0% by weight Hydroxypropylcellulose 1.0% by weight As in Example 1, an external use powder having the above composition was used. Manufactured.
【0020】[0020]
【発明の効果】本発明によれば、流動性および吸水性に
優れたポビドンヨード含有の皮膚潰瘍用外用散剤が得ら
れる。本発明の製剤は流動性のある散剤であるため、取
り扱いが容易であり、創面に隈無く密着するよう塗布す
ることができる。また、吸水性に優れているので、創面
からの滲出液を吸収することができ、創面の乾燥化、細
菌感染の抑制、肉芽形成の促進をもたらすことができ
る。さらに、本発明によれば、使用後の創面からの除去
が容易な皮膚潰瘍用外用散剤が得られる。本発明の散剤
は滲出液を吸収して弾力のある塊となり、創面から剥離
し易くなるので除去が容易となり、水で簡単に洗い流す
ことができる。本発明の外用散剤は、pHを調整しなく
ても経時的に安定であり、また皮膚への刺激性が少な
い。このような利点を有することから、本発明のポビド
ンヨード皮膚潰瘍用外用散剤は、褥蒼、熱傷のような皮
膚潰瘍治療に好適に使用することができる。INDUSTRIAL APPLICABILITY According to the present invention, an external powder for skin ulcer containing povidone iodine having excellent fluidity and water absorbability can be obtained. Since the preparation of the present invention is a flowable powder, it is easy to handle and can be applied so as to be intimately adhered to the wound surface. Further, since it is excellent in water absorption, it can absorb the exudate from the wound surface, which can lead to dryness of the wound surface, suppression of bacterial infection, and promotion of granulation. Furthermore, according to the present invention, an external powder for skin ulcer that can be easily removed from the wound surface after use is obtained. The powder of the present invention absorbs the exudate to form an elastic mass and is easily separated from the wound surface, so that the powder can be easily removed, and can be easily washed off with water. The external use powder of the present invention is stable over time without adjusting the pH, and has little skin irritation. Due to these advantages, the povidone-iodine external powder for skin ulcers of the present invention can be suitably used for the treatment of skin ulcers such as pimples and burns.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 //(A61K 31/79 A61K 9/14 U 33:18 31:70) ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 6 Identification code Internal reference number FI technical display location // (A61K 31/79 A61K 9/14 U 33:18 31:70)
Claims (6)
ス化合物20〜40重量%、結合剤0.5〜3.0重量%
およびヨードホール0.5〜10重量%からなる皮膚潰
瘍用外用散剤。1. Sugar 60 to 80% by weight, water-swellable cellulose compound 20 to 40% by weight, binder 0.5 to 3.0% by weight.
And an external powder for skin ulcer, which comprises 0.5 to 10% by weight of iodine.
用外用散剤。2. The external powder for skin ulcer according to claim 1, wherein the sugar is sucrose.
ドロキシプロピルセルロースである請求項1または2記
載の皮膚潰瘍用外用散剤。3. The external powder for skin ulcer according to claim 1, wherein the water-swellable cellulose compound is low-substituted hydroxypropyl cellulose.
である請求項1乃至3のいずれかの項に記載の皮膚潰瘍
用外用散剤。4. The external powder for skin ulcer according to claim 1, wherein the binder is hydroxypropyl cellulose.
求項1乃至4記載の皮膚潰瘍用外用散剤。5. The external powder for skin ulcers according to claim 1, wherein the iodine hole is povidone iodine.
し、該混合物に低級アルカノールに結合剤を溶解した溶
液を加えて練合し、練合物を乾燥後、整粒した物にヨー
ドホールを加えて混合することからなる請求項1に記載
の皮膚潰瘍用外用散剤の製造方法。6. A sugar and a water-swellable cellulose compound are mixed, a solution of a binder dissolved in a lower alkanol is added to the mixture, and the mixture is kneaded. After drying the kneaded product, iodine is added to the sized product. The method for producing an external powder for skin ulcer according to claim 1, which comprises adding and mixing.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP33314595A JP2953649B2 (en) | 1995-12-21 | 1995-12-21 | Topical powder for skin ulcer |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP33314595A JP2953649B2 (en) | 1995-12-21 | 1995-12-21 | Topical powder for skin ulcer |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09169655A true JPH09169655A (en) | 1997-06-30 |
JP2953649B2 JP2953649B2 (en) | 1999-09-27 |
Family
ID=18262804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP33314595A Expired - Lifetime JP2953649B2 (en) | 1995-12-21 | 1995-12-21 | Topical powder for skin ulcer |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2953649B2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1224937A1 (en) * | 1999-10-22 | 2002-07-24 | Nippi, Incorporated | Stable preparations for treating bedsore, skin ulcer and wound |
WO2004011032A1 (en) * | 2002-07-26 | 2004-02-05 | Mikasa Seiyaku Co., Ltd. | External preparation |
US8323693B2 (en) | 2002-03-14 | 2012-12-04 | Medrx Co., Ltd. | External preparation for wounds |
CN104069070A (en) * | 2014-06-27 | 2014-10-01 | 深圳市格易通消毒药械科技有限公司 | Povidone-iodine powder with effective sterilization and disinfection effects and preparation method thereof |
ITBA20130047A1 (en) * | 2013-06-07 | 2014-12-08 | Simone Tenerelli | COMPOSITION FOR THE PROTECTION AND HEALING OF DECUBITUS, VASCULAR AND DIABETIC ULCERS. |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19957918A1 (en) * | 1999-11-25 | 2001-06-13 | Ulrich Doht | Disinfectant cleaner for cleaning and care and process for its manufacture |
-
1995
- 1995-12-21 JP JP33314595A patent/JP2953649B2/en not_active Expired - Lifetime
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1224937A1 (en) * | 1999-10-22 | 2002-07-24 | Nippi, Incorporated | Stable preparations for treating bedsore, skin ulcer and wound |
EP1224937A4 (en) * | 1999-10-22 | 2007-03-07 | Nippi Inc | Stable preparations for treating bedsore, skin ulcer and wound |
US8323693B2 (en) | 2002-03-14 | 2012-12-04 | Medrx Co., Ltd. | External preparation for wounds |
WO2004011032A1 (en) * | 2002-07-26 | 2004-02-05 | Mikasa Seiyaku Co., Ltd. | External preparation |
ITBA20130047A1 (en) * | 2013-06-07 | 2014-12-08 | Simone Tenerelli | COMPOSITION FOR THE PROTECTION AND HEALING OF DECUBITUS, VASCULAR AND DIABETIC ULCERS. |
CN104069070A (en) * | 2014-06-27 | 2014-10-01 | 深圳市格易通消毒药械科技有限公司 | Povidone-iodine powder with effective sterilization and disinfection effects and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2953649B2 (en) | 1999-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100370313B1 (en) | Powder preparation for healing demaged skin | |
EP0258761B1 (en) | Wound-healing preparations | |
KR940011240B1 (en) | Pharmaceutical composition for forming films on body tissue | |
JPH0567612B2 (en) | ||
JPH10511364A (en) | Stable budezonide solution, process for its preparation and use of said solution as enema and pharmaceutical foam | |
HU229205B1 (en) | Use of biguanide derivatives for preparation of medicament having a wound healing effect | |
DE69119217T2 (en) | COMPOSITIONS FOR CONTROLLED RELEASE | |
US20110104279A1 (en) | Healing powder and method of use thereof | |
EP2292257A2 (en) | Compositions and methods for dermatological wound healing | |
US20110021455A1 (en) | Sterilised sucralfate gel | |
JPH09169655A (en) | Topical powder for skin ulcer | |
CN113713113B (en) | Composition for treating oral mucosa diseases and preparation method thereof | |
CN1814279A (en) | Regenerated human alkali fiber-cell growth factor gel former and preparing method | |
JPS6310716A (en) | Beta-stimulation agent for external use | |
JPH0745406B2 (en) | Method for producing free-flowing and homogeneous wound powder containing iodine | |
JP2000038342A (en) | Pharmaceutical preparation for restoring bedsore and damaged skin | |
JPS6310731A (en) | Stable damaged skin repair formulation | |
JP3472442B2 (en) | Formulation for repairing damaged skin | |
JPH10203963A (en) | Pharmaceutical composition for oral administration containing bactericidal substance and mucoadhesive substance | |
JPS6158445B2 (en) | ||
JPH11100323A (en) | External pharmaceutical preparation | |
EP0436015B1 (en) | Rectally administered pharmaceutical preparation | |
CN116059383B (en) | Flurbiprofen salt gel and crystallization inhibitor thereof | |
JP2705177B2 (en) | Skin ulcer treatment | |
RU2036642C1 (en) | Process for manufacture of long-acting broncholithic medicinal composition based on theophylline |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090716 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090716 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100716 Year of fee payment: 11 |